Corient Private Wealth LP Has $2.92 Million Holdings in Teleflex Incorporated $TFX

Key Points

• Corient Private Wealth increased its Teleflex stake by 460.7% in the second quarter, holding 23,063 shares valued at approximately $2.92 million. Institutional investors collectively own 95.62% of the company.
• Analysts maintain a consensus “Hold” rating on Teleflex, with an average price target of $152.90; Needham raised its target to $170 and assigned a “Buy” rating.
• Teleflex exceeded quarterly earnings expectations, reporting $1.76 in EPS and $570.33 million in revenue, up 28.9% year over year. The company also declared a $0.34 quarterly dividend, representing a 1.1% annualized yield.

Corient Private Wealth LP lifted its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 460.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,063 shares of the medical technology company's stock after purchasing an additional 18,950 shares during the quarter. Corient Private Wealth LP owned 0.05% of Teleflex worth $2,923,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TFX. Kelleher Financial Advisors bought a new position in shares of Teleflex in the second quarter valued at $25,000. Banque Cantonale Vaudoise grew its position in shares of Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company's stock valued at $31,000 after acquiring an additional 113 shares during the period. Allworth Financial LP acquired a new position in shares of Teleflex during the 2nd quarter worth about $44,000. Hantz Financial Services Inc. raised its holdings in shares of Teleflex by 40.5% in the 4th quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company's stock valued at $48,000 after purchasing an additional 113 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Teleflex by 573.4% in the 2nd quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company's stock valued at $55,000 after purchasing an additional 367 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TFX. Mizuho boosted their price target on Teleflex from $140.00 to $145.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 15th. Wall Street Zen raised Teleflex from a "sell" rating to a "hold" rating in a research report on Sunday, August 9th. Truist Financial lifted their target price on Teleflex from $143.00 to $150.00 and gave the stock a "hold" rating in a research note on Monday, August 10th. Weiss Ratings reissued a "sell (d)" rating on shares of Teleflex in a report on Wednesday, June 24th. Finally, Needham & Company LLC increased their price target on Teleflex from $159.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $152.90.

Teleflex Price Performance

Shares of NYSE TFX opened at $124.24 on Tuesday. The stock has a market capitalization of $5.26 billion, a PE ratio of -5.33, a P/E/G ratio of 0.83 and a beta of 0.82. Teleflex Incorporated has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12. The business has a fifty day moving average price of $134.86 and a two-hundred day moving average price of $128.46.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.48. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business's revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities analysts predict that Teleflex Incorporated will post 7.26 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, August 14th. Teleflex's payout ratio is currently -5.84%.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company's portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.